MRSA, once a rare infection mainly acquired in a hospital setting, is now out in the general population. It is very difficult to treat because it is resistant to most antibiotics. Nor is MRSA the only such pathogen out there. More and more are evolving resistance to multiple antibiotics.
There has always been something of an arms race between humans trying to kill disease causing microbes and the microbes themselves. Up to now, we've always been bailed out by the development of new antibiotics. However, pharmaceutical companies have lost interest in developing new antibiotics. Why? To quote a Pharmaceutical executive,
To illustrate the decline in new antibiotics, consider the fact that from 1983-1987 16 new antibiotics were approved by the FDA; but from 2008-2011 that number was only 2.
Furthermore, As recently as 1990 we had 19 companies developing antibiotics, that number has now declined to 4.
There are some acts before congress that are intended to address this issue such as the GAIN bill in the house and the STAAR bill in the senate).
Of course, these bills have yet to be passed and even if they are successful, we are likely to be dealing with an increasing number of superbugs for the foreseeable future.
http://www.medscape.com/viewarticle/751959?src=mp&spon=17
There has always been something of an arms race between humans trying to kill disease causing microbes and the microbes themselves. Up to now, we've always been bailed out by the development of new antibiotics. However, pharmaceutical companies have lost interest in developing new antibiotics. Why? To quote a Pharmaceutical executive,
"You take an antibiotic for 2 weeks, and you take a statin the rest of your life. What would you make?
To illustrate the decline in new antibiotics, consider the fact that from 1983-1987 16 new antibiotics were approved by the FDA; but from 2008-2011 that number was only 2.
Furthermore, As recently as 1990 we had 19 companies developing antibiotics, that number has now declined to 4.
There are some acts before congress that are intended to address this issue such as the GAIN bill in the house and the STAAR bill in the senate).
Of course, these bills have yet to be passed and even if they are successful, we are likely to be dealing with an increasing number of superbugs for the foreseeable future.
http://www.medscape.com/viewarticle/751959?src=mp&spon=17
Last edited: